Oxford Biotheraputics
Lead programs
Lead programs

Progressing our antibody-based cancer treatments

Our most advanced therapies have completed a number of stages of development in preparation for clinical studies. The results of this testing are highly encouraging, and supports our plans to progress the development of these proprietary antibody-drug conjugate (ADC) cancer therapies into the clinic.

OBT357 / MEN1112

Our lead program is the first in our collaboration with Menarini to be designated for clinical development.  The product candidate is a novel enhanced antibody that incorporates BioWa’s POTELLIGENT® technology.  It is designed to induce antibody-dependent cellular cytotoxicity in acute myeloid leukemia and related hematological cancers. This first-in-class therapeutic has demonstrated preclinical proof of concept by inducing the depletion of ex vivo leukemic blasts from AML patients. A Phase I AML dose-escalation study is underway.

To learn more about the program, please see:
     - ASH 2014 A. Venditti
     - ASH 2014 D. Aud
     - ASH 2014 C. Krupka

OX002 / MEN1309

The protein targeted by our OX002 program is highly expressed in triple negative breast cancer.  The protein is also highly expressed in other solid and liquid cancers, providing additional potential target indications.  The ADC incorporates a fully human antibody generated by Amgen and ImmunoGen’s proprietary toxin technology, and has demonstrated therapeutic efficacy in multiple preclinical cancer models. Exploratory preclinical safety testing of a clinically relevant dose has been successfully completed.


Our OX003 program targets a protein that is highly expressed in small cell lung cancer and non-small cell lung cancer.  The ADC is based on a fully human Medarex antibody combined with a DNA toxin.  Tests have demonstrated total tumor clearance in preclinical cancer models, and the ADC has been successfully tested in an exploratory preclinical safety study.